FDA to review market authorisation application for vadadustat for anaemia due to chronic kidney disease in adult patients on dialysis and not on dialysis

Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor. The phase 3 clinical development program has recently been completed. A market authorisation application has not yet been submitted for use in Europe or the UK, but it is licensed for use in Japan.

Source:

Biospace Inc.